EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model
Tóm tắt
Head and neck squamous cell carcinoma (HNSCC) tumours are associated with high mortality despite advances in therapy. The monoclonal antibody cetuximab (Erbitux®) has been approved for the treatment of advanced HNSCC. However, only a subset of HNSC patients receiving cetuximab actually responds to treatment, underlining the need for a means to tailor treatments of individual patients. The aim of the present study was to investigate the effect of cetuximab treatment on tumour growth, on tumour partial oxygen pressure as measured by LiPc electron paramagnetic resonance oximetry and on the expression of proteins involved in tumour growth, metabolism and hypoxia. Two HNSCC cell lines, UT-SCC-2 and UT-SCC-14, were used to generate xenografts on female BALB/c (nu/nu) nude mice. Mice with xenografts were given three injections of intraperitoneal cetuximab or phosphate-buffered saline, and the tumour volume was recorded continuously. After treatment the tumour partial oxygen pressure was measured by LiPc electron paramagnetic resonance oximetry and the expression of epidermal growth factor receptor (EGFR), phosphorylated EGFR, Ki-67, MCT1, MCT4, GLUT1, CAIX and HIF-1α were investigated by immunohistochemistry. In xenografts from both cell lines (UT-SCC-2 and UT-SCC-14) cetuximab had effect on the tumour volume but the effect was more pronounced on UT-SCC-14 xenografts. A higher tumour oxygenation was measured in cetuximab-treated tumours from both cell lines compared to untreated controls. Immunocytochemical staining after cetuximab treatment shows a significantly decreased expression of EGFR, pEGFR, Ki67, CAIX and nuclear HIF-1α in UT-SCC-14 tumours compared to untreated controls. MCT1 and GLUT1 were significantly decreased in tumours from both cell lines but more pronounced in UT-SCC-14 tumours. Taken together, our results show that cetuximab treatment decreases the tumour growth and increases the tumour partial oxygen pressure of HNSCC xenografts. Furthermore we found a potential connection between the partial oxygen pressure of the tumours and the expression of proteins involved in tumour growth, metabolism and hypoxia.
Tài liệu tham khảo
Ang, K. K., Berkey, B. A., Tu, X., et al. (2002). Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Research, 62, 7350–7356.
Salamon, D. S., Brandt, R., Ciardeillo, F., Normanno, N. (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. Critical Reviews in Oncology/Hematology, 19, 183–232.
Bonner, J. A., Harari, P. M., Giralt, J., et al. (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. The New England Journal of Medicine, 354, 567–578.
Tsien, C. I., Nyati, M. K., Ahsan, A., et al. (2013). Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma. Head & Neck, 35, 1323–1330.
Brizel, D. M., Dodge, R. K., Clough, R. W., Dewhirst, M. W. (1999). Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiotherapy and Oncology, 53, 113–117.
Stadler, P., Becker, A., Feldmann, H. J., et al. (1999). Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. International Journal of Radiation Oncology, Biology, Physics, 44, 749–754.
Rudat, V., Vanselow, B., Wollensack, P., et al. (2000). Repeatability and prognostic impact of the pretreatment pO 2 histography in patients with advanced head and neck cancer. Radiotherapy and Oncology, 57, 31–37.
Nordsmark, M., Bentzen, S. M., Rudat, V., et al. (2005). Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiotherapy and Oncology, 77, 18–24.
Daşu, A., & Toma-Daşu, I. (2008). Vascular oxygen content and the tissue oxygenation—a theoretical analysis. Medical physics, 35, 539–545.
Eriksen, J. G., & Horsman, M. R. (2006). Tumour hypoxia–a characteristic feature with a complex molecular background. Radiotherapy and Oncology, 81, 119–121.
Toma-Daşu, I., Daşu, A., Waites, A., Denekamp, J., Fowler, J. F. (2002). Theoretical simulation of oxygen tension measurement in the tissue using a microelectrode: II. Simulated measurements in tissues. Radiotherapy and Oncology, 64, 109–118.
Toma-Daşu, I., Daşu, A., Karlsson, M. (2004). The relationship between temporal variation of hypoxia, polarographic measurements and predictions of tumour response to radiation. Physics in medicine and biology, 49, 4463–4475.
Wijffels, K., Kaanders, J., Rijken, P., et al. (2000). Vascular architecture and hypoxic profiles in human head and neck squamous cell carcinomas. British journal of cancer, 83, 674–683.
Koh, W.-J., Bergman, K. S., Rasey, J. S., et al. (1995). Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18] fluoromisonidazole positron emission tomography. International Journal of Radiation Oncology, Biology, Physics, 33, 391–398.
Rasey, J. S., Koh W-j, Evans, M. L., et al. (1996). Quantifying regional hypoxia in human tumors with positron emission tomography of [18 F] fluoromisonidazole: A pretherapy study of 37 patients. International Journal of Radiation Oncology, Biology, Physics, 36, 417–428.
Lee, S. T., & Scott, A. M. (2007). Hypoxia positron emission tomography imaging with 18 F-fluoromisonidazole. Seminars in nuclear medicine, 37, 451–461.
Grosu, A.-L., Souvatzoglou, M., Röper, B., et al. (2007). Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. International Journal of Radiation Oncology, Biology, Physics, 69, 541–551.
Toma-Daşu, I., Daşu, A., Brahme, A. (2009). Quantifying tumour hypoxia by PET imaging-a theoretical analysis. Advances in Experimental Medicine and Biology, 645, 267–272.
Taylor, N. J., Baddeley, H., Goodchild, K. A., et al. (2001). BOLD MRI of human tumor oxygenation during carbogen breathing. Journal of Magnetic Resonance Imaging, 14, 156–163.
Weil, J. A., & Bolton, J. R. (2007). Electron paramagnetic resonance: Elementary theory and practical applications. Hoboken, NJ: Wiley.
Liu, K., Gast, P., Moussavi, M., et al. (1993). Lithium phthalocyanine: A probe for electron paramagnetic resonance oximetry in viable biological systems. Proceedings of the National Academy of Sciences 90, 5438–5442.
Elas, M., Magwood, J. M., Butler, B., et al. (2013). EPR oxygen images predict tumor control by a 50% tumor control radiation dose. Cancer research, 73, 5328–5335.
Swartz, H. M., Williams, B. B., Zaki, B. I., et al. (2014). Clinical EPR: Unique opportunities and some challenges. Academic radiology, 21, 197–206.
Epel, B., Redler, G., Halpern, H. J. (2014). How in vivo EPR measures and images oxygen. Advances in Experimental Medicine and Biology, 812, 113–119.
Elas, M., Ahn, K.-H., Parasca, A., et al. (2006). Electron paramagnetic resonance oxygen images correlate spatially and quantitatively with Oxylite oxygen measurements. Clinical Cancer Research, 12, 4209–4217.
Khan, N., Mupparaju, S., Hou, H., Williams, B. B., Swartz, H. (2012). Repeated assessment of orthotopic glioma pO 2 by multi-site epr oximetry: A technique with the potential to guide therapeutic optimization by repeated measurements of oxygen. Journal of Neuroscience Methods, 204, 111–117.
Franzén, S., Pihl, L., Khan, N., Palm, F., Gustafsson, H. (2014). Repetitive measurements of intrarenal oxygenation in vivo using L-band Electron Paramagnetic Resonance. Advances in Experimental Medicine and Biology, 812, 135–141.
Franzén, S., Pihl, L., Khan, N., Gustafsson, H., Palm, F. (2016). Pronounced kidney hypoxia precedes albuminuria in type 1 diabetic mice. American Journal of Physiology Renal Physiology, 310, F807–F809.
Jerhammar, F., Johansson, A.-C., Ceder, R., et al. (2014). YAP1 is a potential biomarker for cetuximab resistance in head and neck cancer. Oral Oncology, 50, 832–839.
Stoll, S., & Schweiger, A. (2006). EasySpin, a comprehensive software package for spectral simulation and analysis in EPR. Journal of Magnetic Resonance, 178, 42–55.
Gustafsson H., Lund A. (2016). Software for in vivo oximetry by EPR imaging. www.researchgate.net/publication/303988217_Software_for_in_vivo_oximetry_by_EPR_imaging, doi:10.13140/RG.2.1.3783.6406
Denekamp, J., Daşu, A., Waites, A. (1998). Vasculature and microenvironmental gradients: the missing links in novel approaches to cancer therapy? Advances in Enzyme Regulation, 38, 281–299.
Robinson, B., Mailer, C., Reese, A. (1999). Linewidth analysis of spin labels in liquids: I. Theory and data analysis. Journal of Magnetic Resonance, 138, 199–209.
Ljungkvist, A. S., Bussink, J., Rijken, P. F., Kaanders, J. H., van der Kogel, A. J., Denekamp, J. (2002). Vascular architecture, hypoxia, and proliferation in first-generation xenografts of human head-and-neck squamous cell carcinomas. International Journal of Radiation Oncology, Biology, Physics, 54, 215–228.
Toma-Dasu, I., Waites, A., Dasu, A., Denekamp, J. (2001). Theoretical simulation of oxygen tension measurement in tissues using a microelectrode: I. The response function of the electrode. Physiological Measurement, 22, 713–725.
Jedlinski, A., Ansell, A., Johansson, A. C., Roberg, K. (2013). EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines. Journal of Oral Pathology & Medicine, 42, 26–36.
Palm, F., Cederberg, J., Hansell, P., Liss, P., Carlsson, P.-O. (2003). Reactive oxygen species cause diabetes-induced decrease in renal oxygen tension. Diabetologia, 46, 1153–1160.
Ekblad, L., Welinder, C., Kjellén, E., Brun, E., Wennerberg, J. (2015). Anti-or pro-proliferation–Conditional options for TGF-α and cetuximab in head and neck squamous cell carcinoma. Oral Oncology, 51, 46–52.
Curry, J. M., Tuluc, M., Whitaker-Menezes, D., et al. (2013). Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer. Cell Cycle (Georgetown, Tex.), 12, 1371–1384.
Li, X., Lu, Y., Liang, K., Pan, T., Mendelsohn, J., Fan, Z. (2008). Requirement of hypoxia-inducible factor-1α down-regulation in mediating the antitumor activity of the anti–epidermal growth factor receptor monoclonal antibody cetuximab. Molecular Cancer Therapeutics, 7, 1207–1217.
Lu, H., Li, X., Luo, Z., Liu, J., Fan, Z. (2013). Cetuximab reverses the Warburg effect by inhibiting HIF-1–regulated LDH-A. Molecular Cancer Therapeutics, 12, 2187–2199.
Klimowicz, A., Bose, P., Petrillo, S., Magliocco, A., Dort, J., Brockton, N. (2013). The prognostic impact of a combined carbonic anhydrase IX and Ki67 signature in oral squamous cell carcinoma. British Journal of Cancer, 109, 1859–1866.